A practical reference on HGF mimetic: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-09-17 and is reviewed periodically as new material appears.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
In the absence of caffeine and when a person is awake and alert, little adenosine is present in CNS neurons. With a continued wakeful state, over time adenosine accumulates in the neuronal synapse, in turn binding to and activating adenosine receptors found on certain CNS neurons; when activated, these receptors produce a cellular response that ultimately increases drowsiness. When caffeine is consumed, it antagonizes adenosine receptors; in other words, caffeine prevents adenosine from activating the receptor by blocking the location on the receptor where adenosine binds to it. As a result, caffeine temporarily prevents or relieves drowsiness, and thus maintains or restores alertness.
which is, like r, a measure of the principal orientation and disorder of the structure being imaged. Since it is often performed in long cylindrical filaments (like collagen), this anisotropy is often equal to
== Causes == Matrix metalloproteinases (MMP's) are enzymes that promote breakdown of the extracellular matrix. This matrix contains important nutrients and proteins like collagen, elastin, and proteoglycans. All of which are involved in skin health and structure. The MMP levels in a smoker are elevated, causing excessive breakdown of the matrix. Therefore, those essential proteins and antioxidants, like Vitamin C, also begin to disappear. This leaves the skin empty and depleted of its structure, causing hollowness and sagging of the skin. Nearby blood vessels can become damaged by the tobacco extracts and then constrict, reducing flow of oxygen to the face. Oxygen breakdown without circulation causes reactive oxygen species, or ROS and free radicals, to build up. Then skin, now deplete of antioxidants, cannot clean up the free radicals leaving them to build up in the tissues. This eventually leads to oxidative stress. This is attributed to what is called extrinsic aging; known to be caused by external and environmental factors. This can cause skin allergies, skin thinning, wrinkles, issues with pigmentation, cancers and more. Important enzymes like glutathione peroxidase and glutathione reductase, which help clean up the extracellular matrix also become reduced.
=== Crohn's disease === Three phenotypes, or categories of disease, are present in Crohn's disease: stricturing disease (which causes narrowing of the bowel), penetrating disease (which causes fistulae or abnormal connections of the bowel), and inflammatory disease (which primarily causes inflammation).
Sources: en.wikipedia.org
=== Locating trials === Depending on the kind of participants required, sponsors of clinical trials, or contract research organizations working on their behalf, try to find sites with qualified personnel as well as access to people who could participate in the trial. Working with those sites, they may use various recruitment strategies, including patient databases, newspaper and radio advertisements, flyers, posters in places the patients might go (such as doctor's offices), and personal recruitment of trial participants by investigators. Volunteers may search directly to locate trials using a registry run by the U.S. National Institutes of Health and National Library of Medicine to identify studies that are currently recruiting participants, offering simplified navigation and real-time enrollment trial information. Software exists to enable clinicians to find trial options for a possible participant based on genomic data for people with cancer.
, respectively. Michaelis–Menten kinetics relies on the law of mass action, which is derived from the assumptions of free diffusion and thermodynamically driven random collision. Many biochemical or cellular processes deviate significantly from these conditions, because of macromolecular crowding and constrained molecular movement. More recent, complex extensions of the model attempt to correct for these effects.
The following year he was elected to membership at the Institute of Medicine. In 1987, he became Professor Emeritus of Medicine at Harvard Medical School. One year later he was the first Paul Klemperer Award recipient at the New York Academy of Medicine. In 1995, Gross won the Lifetime Achievement Award of The Wound Healing Society.
Sources: en.wikipedia.org
It would tax retirement benefits, creating a 5% pay cut for somebody under the system, while also undermining the merit-based civil service by having an additional 5% cut if you decide to retain those merit-based civil service protections. Those protections don't exist for the purpose of the employee – they exist to protect against politically based firings of federal employees. American Federation of Government Employees (AFGE) national president Everett Kelley stated that:
Equality Consultancy was allegedly set up to cover up the bribes Antonio Panzeri would have received from foreign governments. Giorgi admitted according to the Financial Times helping Antonio Panzeri disguise money received from Morocco and Qatar. Among the clients of the Milan-based consultancy was the UK-based Turkish human rights consultant Hakan Camuz. Hakan Camuz said that he hired the firm for what he called ethical lobbying services, which included facilitating of meetings with members of the European Parliament. Hakan Camus' objective was to lobby for condemnation of war crimes in Syria and he declared having no knowledge of any wrongdoings of Giorgi and Antonio Panzeri. The commercial relationship started with Giorgi approaching him.
She commented that reviving memories of a suit that the majority of the public had forgotten after the initial burst of publicity was the wrong strategy from Taco Bell. In March 2012, Taco Bell teamed up with Frito-Lay and created the Doritos Locos Tacos, which is a taco with a Dorito Nacho Cheese flavored taco shell. In May 2012, Taco Bell released a drink named Mountain Dew A.M, a mixture of Mountain Dew and orange juice. On June 6, 2012, Taco Bell announced it would be testing a new "Cantina Menu" with upscale items in their Kentucky and California restaurants. The new menu was created by celebrity chef Lorena Garcia, and featured the addition of: Black Beans; Cilantro Rice; Citrus & Herb Marinated Chicken; and Cilantro Dressing. The Cool Ranch Doritos Taco, became available to order on March 7, 2013. Shortly before its release, Taco Bell launched a promotion advertising that fans could get the new flavor at its stores a day early if they "just asked" on March 6. However, they neglected to inform the majority of their stores of this – leading to numerous complaints on its social media accounts and news sites from disappointed consumers who were unable to obtain the new taco.
It enables referendums and plebiscites and establishes environmental protection as a fundamental state principle. The former Hanoverian Amt Neuhaus with its parishes of Dellien, Haar, Kaarßen, Neuhaus (Elbe), Stapel, Sückau, Sumte and Tripkau as well as the villages of Neu Bleckede, Neu Wendischthun and Stiepelse in the parish of Teldau and the historic Hanoverian region in the forest district of Bohldamm in the parish of Garlitz transferred with effect from 30 June 1993 from Mecklenburg-Vorpommern to Lower Saxony (Lüneburg district). From these parishes the new municipality of Amt Neuhaus was created on 1 October 1993. In 1998 Gerhard Glogowski succeeded Gerhard Schröder who became Federal Chancellor. Because he had been linked with various scandals in his home city of Brunswick, he resigned in 1999 and was replaced by Sigmar Gabriel. From 2003 to his election as Federal President in 2010 Christian Wulff was minister president in Lower Saxony. The Osnabrücker headed a CDU-led coalition with the FDP as does his successor, David McAllister. After the elections on 20 January 2013 McAllister was deselected.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.